Medherant: Difference between revisions
linking shortly |
|||
| Line 24: | Line 24: | ||
Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company intends to introduce patches in 2019 which are able to deliver drugs via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref> | Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company intends to introduce patches in 2019 which are able to deliver drugs via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref> | ||
M | |||
==References== | ==References== | ||
Revision as of 09:13, 11 December 2020
Template:Use dmy dates Template:Use British English Template:Self-published
Medherant Ltd is a British pharmaceutical company currently based in Coventry. The company develops over-the-counter (OTC) and prescription transdermal patches for drug delivery.
History
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014.
Research
Using its research in bioadhesives and polymer chemistry, the company intends to introduce patches in 2019 which are able to deliver drugs via the transepidermal route.[1] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process.[2]
M
References
- ↑ "Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin". University of Warwick. https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/. Retrieved on 16 October 2016.
- ↑ "Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines". Medherant Ltd. http://www.medherant.co.uk/about-us. Retrieved on 16 October 2016.